Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/52554
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Calcific uraemic arteriolopathy: an update
Author: Rogers, N.
Coates, P.
Citation: Current Opinion in Nephrology and Hypertension, 2008; 17(6):629-634
Publisher: Lippincott Williams & Wilkins
Issue Date: 2008
ISSN: 1062-4821
1473-6543
Statement of
Responsibility: 
Rogers, Natasha M; Coates, Patrick Toby H
Abstract: <h4>Purpose of review</h4>Calcific uraemic arteriolopathy (CUA) or calciphylaxis is a rare but important cause of morbidity and mortality in patients with chronic kidney disease. The prevalence of CUA is increasing in patients with renal failure, and the condition is also being recognized in nonuraemic patients.<h4>Recent findings</h4>There has been increasing understanding of the molecular basis of vascular calcification, in particular on the important role of the uraemic microenvironment in the factors implicated in the differentiation of vascular smooth muscle cells into osteoblasts. New options for treatment of hyperphosphataemia and secondary hyperparathyroidism in patients with chronic kidney disease have become available in the last few years and these have begun to be used in patients with CUA. These include bisphosphonates, newer noncalcium/nonaluminium-containing phosphate binders and case reports of use of cinacalcet. Other treatments for CUA that are not targeted directly at calcium/phosphate homeostasis include hyperbaric oxygen and the antioxidant cation chelator sodium thiosulphate.<h4>Summary</h4>Clinicians managing patients with CUA should consider a combination approach of treating deranged calcium/phosphate with newer therapeutic agents and promoting wound healing with other older modalities such as hyperbaric oxygen and sodium thiosulphate infusions. Randomized controlled trials for treatments in CUA are still lacking.
Keywords: Humans
Kidney Diseases
Uremia
Vascular Diseases
Calciphylaxis
Chronic Disease
Phosphates
Thiosulfates
Calcium
Chelating Agents
Treatment Outcome
Hyperbaric Oxygenation
Risk Factors
Description: Copyright © 2008 Lippincott Williams & Wilkins, Inc.
DOI: 10.1097/MNH.0b013e32830f4566
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.